Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

No teen herd immunity for 4CMenB in landmark trial

Publish date:: August 21, 2019

Key clinical point: Meningococcal serogroup B vaccine programs should provide direct protection for those at highest risk.

Major finding: The rate of acquisition of carriage of disease-causing genogroups of Neisseria meningitidis in adolescents 12 months post vaccination with 4CMenB was identical to that in unvaccinated controls.

Study details: This prospective, cluster-randomized trial included nearly 35,000 high school students in the state of South Australia.

Disclosures: The presenter reported receiving research funding from GlaxoSmithKline, the major study sponsor.

Citation:

REPORTING FROM ESPID 2019

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Pediatrics

Annual WCC visits significantly limit asthma worsening,

Does daily inhaler monitoring improve asthma outcomes in children?,

More severe AD correlates with worse sleep health and attention problems in children,

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

Shortcomings identified in study of acne videos on TikTok,